Axsome Therapeutics to Report First Quarter 2025 Financial Results on May 5
Axsome Therapeutics (NASDAQ: AXSM), a biopharmaceutical company focused on central nervous system (CNS) disorders, has scheduled its first quarter 2025 financial results announcement for Monday, May 5, 2025, before U.S. markets open.
The company will host a conference call at 8:00 a.m. Eastern Time on the same day, featuring management discussion of results and business updates. Investors can join via phone at (877) 405-1239 (domestic) or +1 (201) 389-0851 (international), or watch the webcast through Axsome's website. A replay will be available online for approximately 30 days after the event.
Axsome Therapeutics (NASDAQ: AXSM), un'azienda biofarmaceutica focalizzata sui disturbi del sistema nervoso centrale (SNC), ha programmato l'annuncio dei risultati finanziari del primo trimestre 2025 per lunedì 5 maggio 2025, prima dell'apertura dei mercati statunitensi.
L'azienda ospiterà una conferenza telefonica alle 8:00 a.m. Eastern Time nello stesso giorno, con una discussione da parte della direzione sui risultati e aggiornamenti aziendali. Gli investitori possono partecipare telefonicamente al numero (877) 405-1239 (nazionale) o +1 (201) 389-0851 (internazionale), oppure guardare la diretta streaming attraverso il sito web di Axsome. Una registrazione sarà disponibile online per circa 30 giorni dopo l'evento.
Axsome Therapeutics (NASDAQ: AXSM), una compañía biofarmacéutica enfocada en trastornos del sistema nervioso central (SNC), ha programado el anuncio de sus resultados financieros del primer trimestre de 2025 para el lunes 5 de mayo de 2025, antes de la apertura de los mercados en EE. UU.
La compañía llevará a cabo una llamada de conferencia a las 8:00 a.m. hora del Este el mismo día, donde la dirección discutirá los resultados y actualizaciones del negocio. Los inversores pueden unirse por teléfono al (877) 405-1239 (nacional) o +1 (201) 389-0851 (internacional), o ver la transmisión en vivo a través del sitio web de Axsome. Una repetición estará disponible en línea durante aproximadamente 30 días después del evento.
Axsome Therapeutics (NASDAQ: AXSM), 중추신경계(CNS) 질환에 집중하는 생물의약품 회사가 2025년 5월 5일 월요일에 미국 시장이 열리기 전에 2025년 1분기 재무 결과 발표를 예정하고 있습니다.
회사는 같은 날 동부 표준시 기준 오전 8시에 경영진이 결과 및 사업 업데이트에 대해 논의하는 컨퍼런스 콜을 개최할 예정입니다. 투자자들은 (877) 405-1239(국내) 또는 +1 (201) 389-0851(국제)로 전화로 참여하거나 Axsome 웹사이트를 통해 웹캐스트를 시청할 수 있습니다. 이벤트 후 약 30일 동안 온라인에서 다시 볼 수 있습니다.
Axsome Therapeutics (NASDAQ: AXSM), une entreprise biopharmaceutique axée sur les troubles du système nerveux central (SNC), a prévu l'annonce de ses résultats financiers du premier trimestre 2025 pour le lundi 5 mai 2025, avant l'ouverture des marchés américains.
L'entreprise organisera une conférence téléphonique à 8h00 heure de l'Est le même jour, au cours de laquelle la direction discutera des résultats et des mises à jour commerciales. Les investisseurs peuvent participer par téléphone au (877) 405-1239 (national) ou au +1 (201) 389-0851 (international), ou regarder le webinaire sur le site Web d'Axsome. Un enregistrement sera disponible en ligne pendant environ 30 jours après l'événement.
Axsome Therapeutics (NASDAQ: AXSM), ein biopharmazeutisches Unternehmen, das sich auf Störungen des zentralen Nervensystems (ZNS) konzentriert, hat die Bekanntgabe seiner finanziellen Ergebnisse für das erste Quartal 2025 auf Montag, den 5. Mai 2025, vor der Eröffnung der US-Märkte festgelegt.
Das Unternehmen wird am selben Tag um 8:00 Uhr Eastern Time eine Telefonkonferenz abhalten, in der das Management die Ergebnisse und Unternehmensupdates bespricht. Investoren können sich telefonisch unter (877) 405-1239 (national) oder +1 (201) 389-0851 (international) einwählen oder die Webcast-Übertragung über die Website von Axsome verfolgen. Eine Aufzeichnung wird etwa 30 Tage nach der Veranstaltung online verfügbar sein.
- None.
- None.
NEW YORK, April 08, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced it will report its financial results for the first quarter of 2025 on Monday, May 5, 2025, before the opening of the U.S. financial markets. Axsome management will then host a conference call at 8:00 a.m. Eastern Time to discuss these results and provide a business update.
To participate in the live conference call, please dial (877) 405-1239 (toll-free domestic) or +1 (201) 389-0851 (international). A live webcast of the conference call can be accessed on the “Webcasts & Presentations” page of the “Investors” section of the Company’s website at www.axsome.com. A replay of the conference call will be available on the Company’s website for approximately 30 days following the live event.
About Axsome Therapeutics
Axsome Therapeutics is a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) conditions. We deliver scientific breakthroughs by identifying critical gaps in care and develop differentiated products with a focus on novel mechanisms of action that enable meaningful advancements in patient outcomes. Our industry-leading neuroscience portfolio includes FDA-approved treatments for major depressive disorder, excessive daytime sleepiness associated with narcolepsy and obstructive sleep apnea, and migraine, and multiple late-stage development programs addressing a broad range of serious neurological and psychiatric conditions that impact over 150 million people in the United States. Together, we are on a mission to solve some of the brain’s biggest problems so patients and their loved ones can flourish. For more information, please visit us at www.axsome.com and follow us on LinkedIn and X.
Forward Looking Statements
Certain matters discussed in this press release are “forward-looking statements”. The Company may, in some cases, use terms such as “predicts,” “believes,” “potential,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. In particular, the Company’s statements regarding trends and potential future results are examples of such forward-looking statements. The forward-looking statements include risks and uncertainties, including, but not limited to, the commercial success of the Company’s Sunosi®, Auvelity®, and Symbravo® products and the success of the Company’s efforts to obtain any additional indication(s) with respect to solriamfetol and/or AXS-05; the Company’s ability to maintain and expand payer coverage; the success, timing and cost of the Company’s ongoing clinical trials and anticipated clinical trials for the Company’s current product candidates, including statements regarding the timing of initiation, pace of enrollment and completion of the trials (including the Company’s ability to fully fund the Company’s disclosed clinical trials, which assumes no material changes to the Company’s currently projected revenues or expenses), futility analyses and receipt of interim results, which are not necessarily indicative of the final results of the Company’s ongoing clinical trials, and/or data readouts, and the number or type of studies or nature of results necessary to support the filing of a new drug application (“NDA”) for any of the Company’s current product candidates; the Company’s ability to fund additional clinical trials to continue the advancement of the Company’s product candidates; the timing of and the Company’s ability to obtain and maintain U.S. Food and Drug Administration (“FDA”) or other regulatory authority approval of, or other action with respect to, the Company’s product candidates, including statements regarding the timing of any NDA submission; the Company’s ability to successfully defend its intellectual property or obtain the necessary licenses at a cost acceptable to the Company, if at all; the successful implementation of the Company’s research and development programs and collaborations; the success of the Company’s license agreements; the acceptance by the market of the Company’s products and product candidates, if approved; the Company’s anticipated capital requirements, including the amount of capital required for the commercialization of Sunosi, Auvelity, and Symbravo and for the Company’s commercial launch of its other product candidates, if approved, and the potential impact on the Company’s anticipated cash runway; the Company’s ability to convert sales to recognized revenue and maintain a favorable gross to net sales; unforeseen circumstances or other disruptions to normal business operations arising from or related to domestic political climate, geo-political conflicts or a global pandemic and other factors, including general economic conditions and regulatory developments, not within the Company’s control. The factors discussed herein could cause actual results and developments to be materially different from those expressed in or implied by such statements. The forward-looking statements are made only as of the date of this press release and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.
Investors:
Mark Jacobson
Chief Operating Officer
(212) 332-3243
mjacobson@axsome.com
Media:
Darren Opland
Director, Corporate Communications
(929) 837-1065
dopland@axsome.com
FAQ
When will Axsome Therapeutics (AXSM) release Q1 2025 earnings?
How can investors join Axsome's (AXSM) Q1 2025 earnings call?
Where can I find the replay of Axsome's (AXSM) Q1 2025 earnings call?
What time is Axsome Therapeutics' (AXSM) Q1 2025 earnings call?
